Therapy Shows Improved Vision in Rare Mitochondrial Disease, Follow-up Results Show
Patients with Leber’s hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that leads to vision loss, show sustained improvement in a follow-up to a Phase 1/2 clinical trial with GenSight Biologics’ therapy candidate GS010. Patients recruited to the study had been diagnosed with LHON for approximately six years.